Advertisement

Topics

Sanofi and Regeneron announce approval of Kevzara® (sarilumab) to treat adult patients with moderately to severely active rheumatoid arthritis in the European Union

06:00 EDT 28 Jun 2017 | PharmaNews.EU

SanofiSanofi and Regeneron Pharmaceuticals, Inc. announced that the European Commission (EC) has granted marketing authorization for Kevzara® (sarilumab) in combination with methotrexate (MTX) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to - or who are intolerant to - one or more disease modifying anti-rheumatic drugs (DMARDs),

Original Article: Sanofi and Regeneron announce approval of Kevzara® (sarilumab) to treat adult patients with moderately to severely active rheumatoid arthritis in the European Union

NEXT ARTICLE

More From BioPortfolio on "Sanofi and Regeneron announce approval of Kevzara® (sarilumab) to treat adult patients with moderately to severely active rheumatoid arthritis in the European Union"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...